Ryan Dennis, MD
Internal Medicine · Oklahoma City, OKNPI 1992930564
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 66.5% of it on its own, with 11 other manufacturers making up the rest.
Across 71 payments — averaging $37.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medtronic$566
- AstraZeneca$93
- Lilly USA, LLC$47
- AbbVie$29
- Acarix USA Inc.$28
- plus $133 from 6 others
What the payments were for
- Food & beverage$2,673100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 42 | $1,777 |
| Medtronic | 10 | $566 |
| AstraZeneca | 6 | $93 |
| Lilly USA, LLC | 3 | $47 |
| AbbVie | 2 | $29 |
| Acarix USA Inc. | 1 | $28 |
| Novo Nordisk | 2 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Boehringer Ingelheim | 1 | $25 |
| Mylan Specialty L.p. | 1 | $21 |
| Amgen | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Connect HF$401
- EnSite Precision Cardiac Mapping System$159
- ENSITE PRECISION$139
- CardioMEMS HF System$128
- AVEIR$127
How this compares
$2,673 in reported general payments places this provider in the 80th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 15 | $17,847 |
| MounjaroTirzepatide | 17 | $17,821 |
| JardianceEmpagliflozin | 12 | $17,429 |
| EliquisApixaban | 23 | $16,276 |
| FarxigaDapagliflozin Propanediol | 14 | $12,495 |
| SynjardyEmpagliflozin/Metformin Hcl | 12 | $6,959 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 134 | $3,719 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $2,639 |
| Sumatriptan | 17 | $2,339 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 80 | $1,924 |
| Fluticasone Propionate | 64 | $1,402 |
| Memantine Hcl | 16 | $1,209 |
| Atorvastatin Calcium | 141 | $1,208 |
| Gabapentin | 111 | $1,167 |
| Tamsulosin Hcl | 89 | $1,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy | $25 | $24,38824 claims |
| Novo NordiskOzempic | $27 | $17,84715 claims |
| Lilly USA, LLCMounjaro | $47 | $17,82117 claims |
| AstraZenecaFarxiga | $93 | $12,49514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Oklahoma City
- Ryan MorganOklahoma City$235K
- Ali JafryOklahoma City$33K
- Samid FarooquiOklahoma City$20K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
- Zain Ul Abideen AsadOklahoma City$14K
- Stuart SchraderOklahoma City$12K
- Patrick GarrisonOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.